Education
About Us
Working with TipRanks
Follow Us
Wave Life Sciences (WVE)
NASDAQ:WVE
WVE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.25 - $16.74
Previous CloseN/A
Volume104.35K
Average Volume (3M)983.46K
Market Cap
$1.55B
Enterprise Value$811.12M
Total Cash (Recent Filing)$180.92M
Total Debt (Recent Filing)$30.53M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
May 08, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding153,486,020
10 Day Avg. Volume955,926
30 Day Avg. Volume983,460
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.59
Price to Cash Flow (P/CF)-8.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.49
Enterprise Value/Ebitda-5.66
Forecast
1Y Price Target
$21.44Price Target Upside127.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Wave Life Sciences News
PremiumCompany Announcements
Wave Life Sciences Reports Positive Phase 2 Trial Results
PremiumCompany Announcements
Wave Life Sciences’ Earnings Call Highlights Progress and Challenges
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe speed of full enrollment of the first single dose cohort in the Phase 1 INLIGHT study of WVE-007 for obesity is encouraging.
Regulatory ProgressWVE is planning multiple clinical trial applications for WVE-003 in Huntington's disease, with supportive feedback from the FDA.
Strategic FocusWave Life Sciences' strategic focus on high-value opportunities in DMD and RNA editing enhances its attractiveness to future partners.
Bears Say
Data AvailabilityBEAM-302's current data is only available for lung patients, suggesting that further safety data in liver patients could be crucial, especially regarding potential liver enzyme elevations.
Safety ConcernsUnresolved questions about potential off-target editing with BEAM-302, which were not addressed, could impact safety assessments.
---
Ownership Overview
27.09% Insiders
10.70% Mutual Funds
0.02% Other Institutional Investors
55.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
WVE FAQ
What was Wave Life Sciences’s price range in the past 12 months?
Wave Life Sciences lowest stock price was $4.25 and its highest was $16.73 in the past 12 months.
What is Wave Life Sciences’s market cap?
Wave Life Sciences’s market cap is $1.55B.
When is Wave Life Sciences’s upcoming earnings report date?
Wave Life Sciences’s upcoming earnings report date is May 08, 2025 which is in 42 days.
How were Wave Life Sciences’s earnings last quarter?
Wave Life Sciences released its earnings results on Mar 04, 2025. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of -$0.179 by $0.359.
Is Wave Life Sciences overvalued?
According to Wall Street analysts Wave Life Sciences’s price is currently Undervalued.
Does Wave Life Sciences pay dividends?
Wave Life Sciences does not currently pay dividends.
What is Wave Life Sciences’s EPS estimate?
Wave Life Sciences’s EPS estimate is -0.26.
How many shares outstanding does Wave Life Sciences have?
Wave Life Sciences has 153,486,020 shares outstanding.
What happened to Wave Life Sciences’s price movement after its last earnings report?
Wave Life Sciences reported an EPS of $0.18 in its last earnings report, beating expectations of -$0.179. Following the earnings report the stock price went up 11.741%.
Which hedge fund is a major shareholder of Wave Life Sciences?
Currently, no hedge funds are holding shares in WVE
---
Wave Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.44 (127.12% Upside)
$21.44 (127.12% Upside)
Blogger Sentiment
Bullish
WVE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
63.32%
12-Months-Change
Fundamentals
Return on Equity
-73.24%
Trailing 12-Months
Asset Growth
28.10%
Trailing 12-Months
Company Description
Wave Life Sciences
Wave Life Sciences (WVE) is a biotechnology company that focuses on the discovery and development of stereopure oligonucleotide therapeutics. The company's approach is based on its proprietary platform, which is designed to deliver highly selective and precisely targeted medicines for genetic diseases. Wave Life Sciences operates primarily in the pharmaceutical and biotechnology sectors, aiming to address rare and genetic disorders through its innovative therapeutic solutions.
---
WVE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive developments, including advancements in clinical programs, a strong financial position, and innovative breakthroughs in RNA editing. However, there were notable challenges such as increased R&D expenses and a net loss for the year. The sentiment is overall positive due to the significant progress and potential of the pipeline.Read More>---
WVE Stock 12 Month Forecast
Average Price Target
$21.44
▲(127.12% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Moderna
―
Best Analysts Covering WVE
1 Year
1 Year Success Rate
10/13 ratings generated profit
1 Year Average Return
+52.44%
reiterated a buy rating 22 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +52.44% per trade.
---